Partnering05

Numab offers its cutting-edge discovery engine to partners looking to develop innovative antibody-based therapeutics with multiple specificities, tailored half-lives, unrivalled potency, and ready to be taken into preclinical and process development. Our disclosed partners are Kaken, Ono, Intarcia and Tillotts.

Partners

Ono Pharmaceutical Co., Ltd.

Kaken Pharmaceutical Co., Ltd.

Intarcia Therapeutics, Inc.

Tillotts Pharma AG

Ono Pharmaceutical Co., Ltd.

Ono Pharmaceutical Co., Ltd., headquartered in Osaka, Japan, is an R&D-oriented pharmaceutical company committed to create innovative medicines in specific areas. It focuses especially on the oncology and diabetes areas. With the launch of the world’s first PD-1 immune checkpoint inhibitor, Opdivo® (nivolumab), Ono is a pioneer in the field of immuno-oncology. For more information, please visit the company’s website at http://www.ono.co.jp/eng/index.html.

Kaken Pharmaceutical Co., Ltd.

Kaken Pharmaceutical Co., Ltd. is a specialty pharmaceutical company in Japan with strong experience in developing and commercializing novel pharmaceuticals and medical devices in the fields of orthopedics, dermatology and surgery. The Company concentrates its R&D resources in inflammation/immunology (dermatitis, rheumatoid arthritis and osteoarthritis), pain relief and fungal infection areas.

For more information, please visit http://www.kaken.co.jp/english/

 

Intarcia Therapeutics, Inc.

Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to enhance treatment outcomes by optimizing and improving the efficacy, continuous administration and tolerability of drug therapies. In addition, delivering medicines just once or twice-yearly has the potential to ensure improved patient adherence and compliance, which is very poor in most chronic diseases. Intarcia’s drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above-body temperature and to deliver them in a continuous and consistent manner via Intarcia’s proprietary technology platform. Intarcia has successfully completed its FREEDOM Phase 3-stage development program for type 2 diabetes, which consisted of four separate clinical trials. Intarcia continues to conduct research and development, utilizing its platform technology, to treat other chronic serious disorders in the field of diabetes and obesity. For more information please visit www.intarcia.com.

Tillotts Pharma AG

Tillotts Pharma AG, part of the Zeria Group, is a fast-growing specialty pharma company with 200 employees in Switzerland and abroad. Tillotts is dedicated to the development, in/out-licensing and commercialization of innovative pharmaceutical products, medical devices and diagnostics, all in the field of gastroenterology. Tillotts successfully markets its own products Asacol® and Colpermin® as well as in-licensed products, such as Simtomax®, in over 55 countries through its own affiliates within Europe and a carefully chosen network of gastroenterology-focused marketing partners throughout the world. For more information please visit www.tillotts.com.